Patents Assigned to GLYTECH, LLC
-
Publication number: 20240277728Abstract: Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent.Type: ApplicationFiled: April 26, 2024Publication date: August 22, 2024Applicant: Glytech LLCInventor: Daniel C. Javitt
-
Patent number: 11969431Abstract: Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent.Type: GrantFiled: January 1, 2021Date of Patent: April 30, 2024Assignee: Glytech LLCInventor: Daniel C. Javitt
-
Publication number: 20230201193Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.Type: ApplicationFiled: February 13, 2023Publication date: June 29, 2023Applicant: Glytech LLCInventor: Daniel C. Javitt
-
Patent number: 11576911Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.Type: GrantFiled: March 9, 2020Date of Patent: February 14, 2023Assignee: GLYTECH LLCInventor: Daniel C. Javitt
-
Publication number: 20220323435Abstract: This application relates to combination compositions for use in treatment of depression, comprising an effective amount of an N-methyl-D-aspartate receptor (NMDAR) antagonist combined with an anti-depressant agent or an atypical antipsychotic approved for treatment of depression. In a preferred embodiment, D-cycloserine is administered at a dose of about 10 mg/kg/d and is formulated to produce sustained blood levels in excess of about 25 microgram/mL.Type: ApplicationFiled: June 20, 2022Publication date: October 13, 2022Applicant: Glytech LLCInventor: Daniel C. Javitt
-
Publication number: 20220143041Abstract: Described herein are compositions, including an oral dosage regimen, for the treatment of NMDAR-related neuropsychiatric disorders such as depression and obsessive-compulsive disorder and that includes an NMDAR antagonist, such as D-cycloserine formulated to produce plasma levels in excess of 25 microgram/mL, combined with more recently developed antidepressants.Type: ApplicationFiled: January 28, 2022Publication date: May 12, 2022Applicant: Glytech LLCInventor: Daniel C. Javitt
-
Publication number: 20210128579Abstract: Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent.Type: ApplicationFiled: January 1, 2021Publication date: May 6, 2021Applicant: Glytech LLCInventor: Daniel C. Javitt
-
Patent number: 10881665Abstract: Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent.Type: GrantFiled: May 24, 2018Date of Patent: January 5, 2021Assignee: GLYTECH, LLCInventor: Daniel C. Javitt
-
Publication number: 20200206219Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.Type: ApplicationFiled: March 9, 2020Publication date: July 2, 2020Applicant: Glytech LLCInventor: Daniel C. Javitt
-
Patent number: 10660887Abstract: Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.Type: GrantFiled: July 16, 2017Date of Patent: May 26, 2020Assignee: GLYTECH, LLCInventor: Daniel C. Javitt
-
Patent number: 10583138Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.Type: GrantFiled: May 24, 2018Date of Patent: March 10, 2020Assignee: GLYTECH, LLCInventor: Daniel C. Javitt
-
Publication number: 20190054085Abstract: This application relates to combination compositions for use in treatment of depression, comprising an effective amount of an N-methyl-D-aspartate receptor (NMDAR) antagonist combined with an anti-depressant agent or an atypical antipsychotic approved for treatment of depression. In a preferred embodiment, D-cycloserine is administered at a dose of about 10 mg/kg/d and is formulated to produce sustained blood levels in excess of about 25 microgram/mL.Type: ApplicationFiled: October 21, 2018Publication date: February 21, 2019Applicant: Glytech LLCInventor: Daniel C. Javitt
-
Publication number: 20180338956Abstract: Described herein are compositions, including an oral dosage regimen, for the treatment of NMDAR-related neuropsychiatric disorders such as depression and obsessive-compulsive disorder and that includes an NMDAR antagonist, such as D-cycloserine formulated to produce plasma levels in excess of 25 microgram/mL, combined with more recently developed antidepressants.Type: ApplicationFiled: May 24, 2018Publication date: November 29, 2018Applicant: Glytech LLCInventor: Daniel C. Javitt
-
Publication number: 20180338983Abstract: Provided herein are compositions for reducing symptoms of post-traumatic stress disorder. The compositions include a combination of an N-methyl-D-aspartate (NMDA) receptor antagonist and an anti-depression agent.Type: ApplicationFiled: May 24, 2018Publication date: November 29, 2018Applicant: Glytech LLCInventor: Daniel C. Javitt
-
Publication number: 20180263976Abstract: This application relates to combination compositions for use in treatment of depression, and which can alleviate the anxiogenic side effects of certain antidepressant and antipsychotic medications. Methods for treatment of depression and medicament side effects, particular anxiety, akathisia, and associated suicidality are also described herein.Type: ApplicationFiled: May 24, 2018Publication date: September 20, 2018Applicant: Glytech LLCInventor: Daniel C. Javitt
-
Publication number: 20170312275Abstract: Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.Type: ApplicationFiled: July 16, 2017Publication date: November 2, 2017Applicant: Glytech, LLCInventor: Daniel C. Javitt
-
Patent number: 9737531Abstract: Compositions and methods tor the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present invention is also directed to methods for the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.Type: GrantFiled: July 7, 2013Date of Patent: August 22, 2017Assignee: GLYTECH, LLCInventor: Daniel C Javitt
-
Patent number: 9486453Abstract: Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.Type: GrantFiled: September 3, 2015Date of Patent: November 8, 2016Assignee: Glytech LLCInventor: Daniel C. Javitt
-
Publication number: 20150374684Abstract: Compositions and methods for the treatment of depression and psychoses in humans are disclosed. More particularly, the invention is directed to formulations containing antipsychotic and/or antidepressant medications and also containing an NMDAR antagonist. The present Invention Is also directed to methods tor the treatment of humans suffering from depression and other psychoses, including, schizophrenia, by administration of the inventive compositions in antidepressant and/or antipsychotic effective amounts.Type: ApplicationFiled: September 3, 2015Publication date: December 31, 2015Applicant: GLYTECH, LLCInventor: Daniel C. Javitt
